| Literature DB >> 32340232 |
Giulio Poli1, Carlotta Granchi1, Flavio Rizzolio2,3, Tiziano Tuccinardi1.
Abstract
Computer-aided drug design techniques are today largely applied in medicinal chemistry. In particular, receptor-based virtual screening (VS) studies, in which molecular docking represents the gold standard in silico approach, constitute a powerful strategy for identifying novel hit compounds active against the desired target receptor. Nevertheless, the need for improving the ability of docking in discriminating true active ligands from inactive compounds, thus boosting VS hit rates, is still pressing. In this context, the use of binding free energy evaluation approaches can represent a profitable tool for rescoring ligand-protein complexes predicted by docking based on more reliable estimations of ligand-protein binding affinities than those obtained with simple scoring functions. In the present review, we focused our attention on the Molecular Mechanics-Poisson Boltzman Surface Area (MM-PBSA) method for the calculation of binding free energies and its application in VS studies. We provided examples of successful applications of this method in VS campaigns and evaluation studies in which the reliability of this approach has been assessed, thus providing useful guidelines for employing this approach in VS.Entities:
Keywords: MM-PBSA; docking; rescoring; virtual screening
Year: 2020 PMID: 32340232 PMCID: PMC7221544 DOI: 10.3390/molecules25081971
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Enrichments (%) obtained for the top-scored 500 compounds of ABL, ALK, and BRAF databases, using Autodock (ADT) and the different Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) and Molecular Mechanics-Poisson Boltzman Surface Area (MM-PBSA) methods tested by Hou and co-workers.
Figure 2Structures of the five ligands selected through the virtual screening (VS) study (compounds 17–21) performed by Grazioso and co-workers, together with the reference compound (22).
Predicted binding free energies (kcal/mol) and experimental IC50 values (µM) for VIR-165, VIR-175 and their variants selected through the virtual screening (VS) study of Venken and co-workers. IC50 values obtained using X4-tropic and R5-tropic human immunodeficiency virus type 1 (HIV-1) virus are reported as IC50 X4 and IC50 R5, respectively.
| VIR Peptide Variant | ΔGbind | IC50 X4 | IC50 R5 |
|---|---|---|---|
| VIR-165 (reference) | −36.92 | 0.34 | 0.59 |
| VIR-175 (reference) | −32.66 | 0.47 | 0.20 |
| VIR-165_V19T | −41.35 | 0.83 | 0.51 |
| VIR-165_I8Q | −41.02 | 1.03 | 0.80 |
| VIR-165_I4Y | −39.52 | 1.10 | 0.30 |
| VIR-165_I4L | −39.43 | 0.62 | 2.03 |
| VIR-165_I8L | −38.8 | 0.35 | 0.83 |
| VIR-165_A13F | −38.19 | 0.22 | 0.46 |
| VIR-165_F18L | −37.88 | 0.48 | 0.40 |
| VIR-165_F14W | −37.28 | 0.33 | 2.51 |
| VIR-165_I4F | −37.21 | 0.40 | 0.26 |
| VIR-165_F18Y | −37.17 | 0.62 | 0.48 |
| VIR-165_F12W | −37.08 | 0.18 | 1.95 |
| VIR-165_S7Q | −36.98 | 0.15 | 0.51 |
| VIR-165_F12L_A13F | −35.76 | 0.13 | 0.41 |
| VIR-165_F12V_A13F_P10A | −40.73 | 0.61 | n.d. a |
| VIR-165_F12V_A13F_F20Y | −36.28 | 0.72 | 1.29 |
| VIR-165_I8Y_F12V_A13F | −36.06 | 0.25 | 0.48 |
| VIR-165_S7N_F12V_A13F | −35.18 | 0.24 | 0.21 |
| VIR-175_I4Q | −36.35 | 1.61 | 0.62 |
| VIR-175_M6L | −35.12 | 0.37 | 0.20 |
| VIR-175_E2Q | −34.74 | 0.77 | 0.69 |
a Not determined.
Figure 3Structure of the 10 ligands selected through the VS study (compounds 1–10) performed by Banoglu and co-workers.
Figure 4Structure of the 12 ligands selected through the VS study (compounds 41–52) performed by Nakagawa and co-workers.
Calculated binding free energies (kcal/mol) and experimental activities of the compound selected through the VS protocol performed by Nakagawa and co-workers.
| Compound N. | ΔGbind | pIC50 |
|---|---|---|
|
| −9.13 | 4.28 |
|
| −9.49 | 5.04 |
|
| −14.01 | < 3.60 |
|
| −9.57 | < 4.00 |
|
| −9.44 | < 4.00 |
|
| −10.73 | 4.13 |
|
| −12.99 | < 3.60 |
|
| −9.61 | 4.11 |
|
| −10.70 | < 3.60 |
|
| −11.01 | 4.12 |
|
| −10.16 | < 3.60 |
|
| −10.51 | < 3.60 |